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ABSTRACT 
According to Bian et al., polymorphonuclear leukocytes (PMN) undergo 
phenotypic changes, suggestive of bone marrow (BM) myeloid reprogramming, 
under chronic inflammatory conditions 1. Utilizing a murine dextran sodium 
sulfate (DSS)-induced colitis-to-recovery model, we characterized the BM 
myeloid compartment during acute, post-acute/chronic, and resolution of 
inflammation. Percoll density gradient separation of BM leukocytes from colitis-
to-recovery mice revealed significant expansion of the immature myeloid 
compartment (IMC) beginning at the post-acute stage and extending until after 
complete inflammation resolution. Additionally, we show that both the mature 
PMN and immature myeloid populations increased production of reactive 
oxygen species (ROS) and demonstrated enhanced infiltration during zymosan-
induced peritonitis. Interestingly, the expanded immature granulocytes not only 
expressed CXCR2 and ARG-1, but also demonstrated potent inhibition of T cell 
proliferation. These findings suggest that the myeloid compartment undergoes 
reprogramming at the post-acute phase producing functionally primed PMN that 
accelerate pathogen clearance, as well as immature Ly6G+CXCR2high 
immunosuppressive effector cells that likely play a role in inflammation recovery 
and tissue repair.  Our study could provide novel strategies for treatment of 
chronic inflammatory diseases such as ulcerative colitis.  
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1 INTRODUCTION 
1.1 Dissertation Introduction  
Acute inflammation is the immediate biological response to injury, infection, 
and trauma. At the site of inflammation, infected tissue resident and damaged 
epithelial/endothelial cells secrete a variety of soluble factors, such as 
interleukin (IL)-1b,IL-6, IL-17, IL-8 etc., required to initiate and perpetuate 
inflammation 1-5. Although, this process involves multiple steps and several cell 
types, leukocytes are found to be crucial for regulation of inflammatory 
responses. Specifically, leukocyte proliferation, differentiation, adhesion, 
migration, and effector functions are required for onset and resolution of acute 
inflammation 3,5,6.   
 
In acute inflammation, the goal of these processes is to rapidly remove the 
extracellular insult, suppress the immune response, and allow for tissue repair 
and return to homeostasis. However, when the insult persists inflammation 
cannot be resolved, resulting in continuous leukocyte infiltration and/or 
functional dysregulation. Hence, leukocytes act as a double-edged sword, 
promoting development of autoimmune and chronic inflammatory disorders like 
inflammatory bowel disease (IBD), arthritis, and cancer 7-9. Furthermore, 
understanding how leukocytes are dynamically regulated during both acute and 
chronic inflammation can provide novel therapeutic strategies for the prevention 
and control of these diseases.  
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1.2 Background 
1.2.1 Polymorphonuclear leukocyte mediated acute inflammation  
In healthy individuals, Ly6GhiLy6C+ polymorphonuclear leukocytes (PMN) 
comprise ~50-60% of total circulating leukocytes, with an average of 1.5 x 1011 
leukocytes being generated in the bone marrow (BM) per day 4,6. PMN that are 
generated in the BM express high levels of chemokine receptor CXCR2 on their 
surfaces. Expression of CXCR2 allows rapid mobilization of PMN in circulation 
under inflammatory conditions, making them the first leukocytes to infiltrate 
the site of inflammation 1,10-12. Once in circulation, PMN use chemotaxis to 
navigate a chemokine gradient of C-X-C motif chemokine ligand 1 (CXCL1), 
CXCL2, IL-8 and infiltrate the inflamed area. To accomplish this, they bind 
selectins on the endothelial membrane with carbohydrate ligands on their 
surface, which initiates PMN tethering, rolling, adhesion, and transmigration 13-
15.  
 
Infiltration of PMN is followed by rapid removal of pathogen, as they possess a 
variety of killing mechanisms that work collaboratively to target extracellular 
insults. These mechanisms include phagocytosis, reactive oxygen species (ROS) 
production, degranulation, and neutrophil extracellular trap (NET) formation 
6,16,17. However, while eliminating pathogens, PMN also damage tissues, thus 
contributing to ongoing inflammation. After preforming their effector functions, 
PMN undergo apoptosis and are cleared by macrophages. Uptake of apoptotic 
PMN induces polarization of M2 macrophages, which are associated with anti-
inflammatory responses and tissue repair 4,18-21. Since PMN are the primary 
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leukocytes responsible for mediating acute inflammation and resolution their 
infiltration and response must be tightly regulated.    
1.2.1.1 PMN recruitment and infiltration 
Several studies have shown that chemokine receptors 2 and 4 (CXCR2 & CXCR4) 
mediate neutrophil retention and release from the BM into circulation 12,22. 
Binding of CXCR4 to its ligand CXCL12 negatively regulates neutrophil exit from 
the BM by inducing secretion of retention factors. CXCL12 is constitutively 
secreted by osteoblasts, vascular endothelial cells, stromal cells, and CXCL12-
abundant reticular cells (CAR) to sequester PMN in the BM at homeostasis 11,23. 
However, during inflammation, high expression of chemokines CXCL8 (IL-8), 
CXCL1, and CXCL2 in the serum override CXCR4/CXCL12 signaling and 
positively regulates neutrophil trafficking by upregulating and ligating CXCR2 
12,24. Ligation of CXCR2 partially activates PMN, facilitates chemotaxis, and 
increases expression of adhesion molecules needed for release into circulation 
and migration into tissues 25,26. Once PMN are recruited into circulation, they 
follow a chemotactic gradient to accumulate at the site of inflammation.  
 
Circulating PMN are tethered to the endothelium by E-,L-, and P- selectins that 
initiate PMN rolling by weakly binding and releasing carbohydrate ligands, such 
as P-selectin glycoprotein ligand-1 (PSGL-1) on their surface 27-29. Rolling allows 
PMN to detect chemokines bound to heparan sulfates on the endothelium. These 
interactions activate PMN and promote firm adhesion to the endothelial 
membrane 30,31. Specifically, CXCL1, CXCL2, CXCL8 have been shown to ligate 
CXCR2 and induce expression of high-affinity integrin mediated binding 
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through conformational changes in the LFA-1 or MAC-1 complexes. LFA-1 and 
MAC1 bind ICAM1 and ICAM2, respectively, on the endothelium to firmly adhere 
PMN 28,32-35.  After adhesion, PMN crawl along the endothelium following a 
chemotactic gradient to identify the preferred site of transmigration. Adhesion 
junction molecules mediate PMN paracellular (at endothelial cell-cell junctions) 
transmigration- it should however be noted that PMN can also transcellularly 
(through an endothelial cell) migrate but prefer the former 13,14,36-39.  
1.2.1.2 PMN response and acute inflammation 
After migrating to the inflamed area, PMN uptake and degrade 
damaged/infected cells and extracellular pathogens by phagocytosis. 
Phagocytosis further activates PMN, inducing degranulation, secretion of ROS, 
and NET formation 40,41. The most notable characteristic of PMN is that they 
possess azurophilic and specific granules comprised of various enzymes and 
antimicrobial peptides required for pathogen killing, including myeloperoxidase 
(MPO), neutrophil elastase (NE), and matrix metalloproteases (MMPs) 15,42-44. 
PMN activation also initiates generation of unstable oxygen radicals that react 
with proteins, lipids, and DNA 45. The presence of ROS during inflammation has 
been shown to play a role in PMN-mediated microbial killing. ROS also facilitate 
PMN infiltration by disrupting the cell membrane and increasing mucosal 
permeability. Under acute inflammatory conditions, tissues like the intestinal 
mucosa use a protective system of antioxidants to counteract any potentially 
harmful effects of ROS 45-48. Interestingly, ROS are also found to contribute to 
PMN apoptosis and angiogenesis during inflammation resolution and tissue 
regeneration, suggesting a role in the anti-inflammatory process 16,49. Similarly, 
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NET formation has been implicated in both inflammation and resolution where 
they were found to induce platelet adhesion, activation, and aggregation 17,50. 
Specifically, ligand binding of PMN Toll-like receptors (TLR) and Fc receptors 
(FcR) initiates the NETosis process. NETs are web-like structures of chromatin 
fibers that contain granular proteins such as NE, cathepsin G, and MPO. 
Invading pathogens are trapped and immobilized/degraded in NETs before 
being phagocytosed by PMN 51-53.  
  
PMN are required for the success of various pro-inflammatory and anti-
inflammatory processes that occur during acute inflammation. Proper clearance 
of extracellular insults is dependent on the infiltration and effector functions of 
these leucocytes. Furthermore, their apoptosis and clearance, ROS production, 
and NET formation serve dual roles by mediating inflammation resolution, as 
well as pathogen eradication. However, because PMN responses are extremely 
potent, their dysregulation can promote development and progression of various 
inflammatory diseases such as experimental autoimmune encephalomyelitis 
(EAE), rheumatoid arthritis (RA), Crohn’s disease, and ulcerative colitis 
1,5,7,43,54,55. Since PMN are required for host immune defense, they cannot be 
completely inhibited. Thus, novel mechanisms are needed to precisely regulate 
PMN infiltration and responses. This dissertation focuses on investigating the 
mechanism of ulcerative colitis using a murine model.  
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1.2.2 Contribution of the PMN response to ulcerative colitis 
development and progression 
PMN have been implicated in the pathogenesis of multiple chronic inflammatory 
diseases. In this study, we used a murine model of ulcerative colitis to 
investigate the role of PMN infiltration and response under inflammatory 
conditions. Colitis is classified as a multifaceted disease that can be attributed to 
an overreactive immune response in the intestines, especially in the colon and 
rectum 54,56-58. When the intestinal epithelium is damaged, PMN are recruited to 
the site of inflammation where their primary purpose is to eliminate the insult.  
 
While the causes of colitis are not well understood, research suggests that a 
combination of genetic susceptibility, immune system dysregulation, and 
microenvironmental factors contribute to an inability to adequately clear the 
insult 4,56,59-61. Failure to remove the extracellular insult results in significantly 
increased proinflammatory cytokine expression and continuous infiltration of 
neutrophils, macrophages, and lymphocytes into the mucosa. Massive migration 
into the inflamed colon causes substantial tissue damage and interrupts the 
tissue regeneration program 57,62-65. Due to this, functionality of the colon and 
rectum can often become impaired, thus promoting the development of 
symptoms such as diarrhea, weight loss, abdominal pain, and rectal bleeding 
58,66.  
 
Multiple studies have shown a significant correlation between PMN 
accumulation in the colon and disease severity in individuals with colitis. 
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Specifically, it was documented that  large numbers of infiltrating PMN damage 
epithelial junction proteins needed for membrane integrity, such as β-catenin, 
E-cadherin, and junction adhesion molecule (JAM)-A. Damaging these proteins 
creates gaps in the endothelium that further promote PMN infiltration and 
facilitate translocation of microbiota, thereby perpetuating the chronic 
inflammatory conditions 7,67-69. In addition to their infiltration/accumulation in 
tissues, PMN responses exhibit a deleterious effect at the site of inflammation.  
1.2.2.1 Regulation of PMN responses during colitis  
Although PMN pathogen killing functions are crucial for host immune defense, 
they are major contributors to colitis disease progression. During post-acute 
colitis PMN display enhanced phagocytosis, which makes them efficient at 
removing extracellular insult. PMN accumulation and increased lifespan in 
tissues under these conditions also leads to a concomitant reduction in apoptosis 
55,70-73. These findings suggest that despite enhanced phagocytosis, infiltrating 
PMN undergo apoptosis at a slower rate resulting in: 1) activated PMN secretion 
of proinflammatory mediators that play a central role in pathogenesis, and 2) an 
exacerbated adaptive immune response due to improper clearance by 
macrophages. Consequently, clearance of apoptotic PMN is important for both 
innate and adaptive immunity.  
 
Another hallmark of chronic inflammation is the imbalance between ROS and 
antioxidants in the colonic mucosa. As a result, PMN consistently produce high 
levels of ROS that cause DNA damage, lipid peroxidation, and protein oxidation. 
Like ROS, high levels of antimicrobial and cytotoxic proteins released by 
8 
degranulating PMN during post-acute colitis can contribute to DNA, lipid, and 
protein damage. The presence of ROS in the colon also mediates autocrine and 
paracrine signaling thereby promoting: PMN, macrophage, dendritic cell (DC), 
and T lymphocyte migration into the inflamed area 45-47,74 . Several studies 
suggest that PMN granule proteins, such as MPO, lipocalin-2 (LCN-2), defensin, 
NE, etc., contribute to the aberrant inflammatory response associated with 
colitis disease progression. Many of these molecules are present in NETs, where 
they perform the same functions on trapped pathogens. Under colitis conditions, 
high numbers of NETs are associated with intestinal bleeding and disease 
severity. Specifically, the increased presence of NETs in the intestine has been 
shown to facilitate the development of small vessel vasculitis and thrombosis 
17,52,53,75.  
 
Clearly, PMN infiltration and response is a major contributor to colitis 
pathology. Loss or inhibition of these functions can also promote chronic 
inflammation. Research shows that impairment of PMN migration by blockade 
of CXCR2 leads to increased levels of commensal bacteria in the intestines of 
dextran sodium sulfate (DSS) -induced colitis mice, a common model of 
ulcerative colitis 25,26. The intricate role of PMN in the transition between acute 
and chronic/post-acute colitis makes it difficult to target these leukocytes and 
their functions. Therefore, there is a need for the development of novel methods 
that can be used to regulate PMN recruitment and responses under chronic 
inflammatory conditions.  
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1.2.2.2 Reprogramming of the bone marrow myeloid compartment under 
chronic inflammatory conditions 
Our group previously published a study investigating the dynamic regulation of 
PMN in both acute and chronic models of inflammation  1. It was found that 
PMN were altered in the BM of colitis mice and that this directly contributed to 
enhanced infiltration of PMN into the colon.  In these experiments, an acute 
inflammatory model, specifically zymosan-induced peritonitis was used as an in 
vivo PMN migration assay. Briefly, zymosan peritonitis was induced in mice 
previously treated with low doses of DSS in water for 14 days (14d) to examine 
PMN response. It was found that ~80% of PMN from chronically inflamed mice 
appear in the peritoneal cavity within 2 hours, compared to healthy mice in 
which ~80% of PMN enter between 4-6 hours. Furthermore, adoptive transfer of 
BM leukocytes from healthy and chronically inflamed mice to healthy mice 
revealed that PMN are functionally altered in the BM of mice during chronic 
inflammation and that this contributed to enhanced infiltration and 
inflammation.  
 
While this paper provided critical  insight into the effects of chronic 
inflammation on PMN infiltration and response, it left open the question of their 
reprogramming in the BM these mice. The purpose of my dissertation was to 
investigate the reprogramming of the BM myeloid compartment under chronic 
inflammatory conditions. Using a DSS-induced colitis-to-recovery model, my 
research focused on answering the following unresolved questions: 1) does 
reprogramming of the myeloid compartment truly occur in the BM , 2) If so, 
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what is the functional significance of this reprogramming, and 3) what factor(s) 
are associated with alterations to the myeloid compartment? Indeed, my 
research shows that PMN become functionally primed in the BM of colitis mice, 
where they display enhanced pathogen killing and migratory capabilities. 
Importantly, we found that the immature myeloid population expand to become 
immunosuppressive granulocytes with high expression of CXCR2. Along with 
enhanced ROS production and migratory potential, these granulocytes also 
displayed characteristics of myeloid derived suppressor cells (MDSC). While the 
role of these leukocytes is unclear, the data suggest they may be involved in 
inflammation resolution and tissue repair.  
1.2.3 Myeloid-derived suppressor cells arise during ulcerative colitis 
MDSC are immunosuppressive myeloid leukocytes that arise under pathological 
conditions including chronic inflammation 76-78. MDSC are derived from 
common myeloid progenitor cells and are regulated by growth factors, 
granulocyte monocyte-colony stimulating factor (GM-CSF), granulocyte- colony 
stimulating factor (G-CSF), and monocyte- colony stimulating factor (M-CSF), 
which are also responsible for myelopoiesis at homeostasis 79-81. Persistent 
proinflammatory signals from the inflamed area induce emergency myelopoiesis 
in the BM to satisfy the increased need for myeloid cells 82-88.  During acute 
inflammation, elevated levels of CSFs in the serum encourage the egress of 
immature myeloid leukocytes from the BM before maturation to replenish the 
circulating PMN population. When the inflammatory condition becomes chronic, 
it is hypothesized that a portion of these leukocytes expand in the BM and 
differentiate into MDSC in circulation after encountering certain signals 89-92. 
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However, new evidence has emerged that suggest otherwise. Specifically, we 
provide evidence demonstrating that immature myeloid leukocytes isolated from 
the BM of DSS colitis mice at the post-acute/chronic phase of treatment already 
display phenotypic, migratory, and immunosuppressive characteristics of MDSC. 
Additionally, extramedullary myelopoiesis was observed in the spleens of these 
mice.  Expansion of MDSC in both the BM and peripheral organs of colitis 
patients is commonly observed. Despite this, few studies have investigated BM 
functional reprogramming of immature myeloid leukocytes into MDSC during 
colitis 85,93-96.  
 
MDSC are not a defined subset of myeloid leukocytes but are instead a 
heterogeneous population of granulocyte and monocyte-like cells arrested at 
various stages of maturation 97-100. These cells are classified as immature due to 
their lack of common activation and maturation markers. Additionally, they 
express a mixture of surface markers specific to myeloid leukocytes but do not 
express lineage markers for T lymphocytes, macrophages, and dendritic cells. 
Murine MDSC are broadly defined by their expression of cell surface markers 
CD11b and Gr1. The Gr1 marker has two isoforms, Lymphocyte antigen 6 
complex C and G; Ly6C is traditionally expressed on monocytes while Ly6G is 
expressed on the surface of granulocytes (PMN). Researchers use the differential 
expression of these isoforms to characterize murine MDSC into two main 
groups, as either M-MDSC or G-MDSC. M-MDSC morphologically resemble 
mononuclear cells, while G-MDSC have been found to be multinucleated and 
have granules like PMN. Recently, multiple new subtypes of immunosuppressive 
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myeloid leukocytes have been identified in humans. Many surface phenotypes 
have been observed, with significant differences found between individuals with 
the same pathological conditions 101-105. This indicates the presence of distinct 
MDSC populations outside of the traditional M-MDSC and G-MDSC subsets 
found in mice. While MDSC phenotypes have been thoroughly characterized in 
mice with colitis, the role they play in its pathology remains unclear.  
1.2.3.1 Characteristics of MDSC 
MDSCs undergoing expansion and reprogramming acquire at least two new 
capabilities. The first is the ability to exit the BM before maturation and 
activation. Under healthy and acute inflammatory conditions, the immature 
myeloid population is sequestered in the BM where they help to maintain an 
immunosuppressive environment. Other studies have also detected small 
numbers of MDSC in the spleen and peripheral blood of mice that display basal 
level suppressive activity, which is likely used to control immune cell tolerance 
in these areas 103,106-108. It is reported that MDSC exit the BM during emergency 
myelopoiesis when inflammatory immature myeloid leukocytes are released to 
assist circulating PMN. Circulating MDSC potently suppress CD4 and CD8 
effector T cell responses through various mechanisms, not only at the site of 
inflammation, but also in lymphoid organs (Fig. 1.1) 109,110.  
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1.2.3.2 Induction and functions of MDSC specific arginase-1  
The best studied mechanism of MDSC suppression is the depletion of L- 
arginine (L-arg) in the microenvironment by arginase-1 (ARG-1)/ inducible 
nitric oxide synthase (iNOS). L-arg is required for T cell development, 
expansion, and activation. MDSC increase expression of ARG-1 to consume L-arg 
from the microenvironment. Removal of L-arg from the microenvironment can 
impair expression of the CD3ζ chain needed to complete the T cell receptor 
(TCR) complex before it can be expressed on the surface of T cells, thereby 
Figure 1.1:MDSC mediated suppression of T cells: 
Diagram depicts the known methods of MDSC suppression of 
T cell proliferation, activation, and migration. 
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inhibiting their activation. In general, lack of L-arg in the microenvironment has 
been correlated with global decreases in protein translation, especially those 
proteins required for T cell cycle progression in 94,111,112. Despite this, there is no 
evidence to support a direct contribution of ARG-1 to MDSC-mediated T cell 
suppression.  
 
The indirect/direct contribution of ARG-1 to MDSC T cell suppressive functions 
is still up for debate. Many articles indicate a direct role for ARG-1 in T cell 
inhibition but have not been able to identify an exact mechanism 110,113-115. 
Conversely, there is strong evidence to support that ARG-1 is not required for 
MDSC-mediated inhibition of T cell proliferation. In one of our studies, MDSCs 
isolated from the BM of tumor-bearing mice were co-cultured with splenic T 
cells, in which T cell proliferation was subsequently induced by TCR-ligation, 
Concanavalin A, PMA plus ionomycin, or IL-2 116. Although they were found to 
potently inhibit T cell proliferation, independent of the method of activation, 
only MDSC cultured with TCR-activated T cells or their media collected after 
proliferation induced ARG-1 expression. To be specific, ARG-1 expression can be 
induced in MDSC by T cell secreted cytokines IL-6, GM-CSF, IL-4, and IL-10. 
Despite displaying immunosuppressive capacity, the lack of ARG-1 expression 
implies that it is not constitutively expressed in MDSC and as such their 
suppressive effects can be independent of its activity. Furthermore, transwell 
assays helped determine that MDSC-mediated T cell suppression is likely 
dependent on cell to cell contact not regulated by programmed death-ligand 1 
(PD-L1) or signal regulatory proteinα (SIRPα). Despite the discrepancies 
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regarding the contribution of ARG-1 to MDSC-mediated suppression, its 
expression can be used as a marker to identify MDSC, as only they and M2 
macrophages express ARG-1.  
1.2.3.3 Inhibition of T cell responses by ROS and iNOS 
G- and M- MDSC both possess ARG-1 but are thought to differentially express 
ROS and iNOS, which acts independently of or cooperatively with ARG-1 to 
supplement its suppressive activity 83,117. Murine G-MDSC predominantly use 
NADPH oxidase to produce ROS that inhibit T cells. Release of ROS, especially 
hydrogen peroxide (H2O2), by G-MDSC acts to impair immature myeloid cell 
differentiation into macrophages and DCs 118,119. On the other hand, murine M-
MDSC use iNOS to metabolize L-arg, resulting in production of nitric oxide 
(NO). M-MDSC secreted NO exerts its immunosuppressive effects on T cells by 
inhibiting Janus kinase (JAK) and signal transducer and activator of 
transcription 3 (STAT3) signaling, reducing major histocompatibility complex 
(MHC) class II surface expression, and inducing T cell apoptosis 120-123.  
 
In humans, all MDSC phenotypes produce ROS. As a result, ROS often combine 
with NO to generate peroxynitrite, the strongest oxidant in the body 83,119,124. 
Peroxynitrite is produced upon direct contact with T cells and its production has 
been shown to prevent tyrosine phosphorylation of proteins required for T cell 
activation 125. Production of peroxynitrite results in nitration of TCR and CD8 
receptor proteins, this causes structural changes in the TCR-CD3 complex that 
reduce the required physical interaction between CD8 and the TCR. Thus, 
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peroxynitrite expression by MDSC leads to loss of TCR antigen recognition and 
disruption of downstream signaling 108,118,126.  
1.2.3.4 Contribution of surface proteins to MDSC mediated T cell suppression  
MDSC constitutively express ADAM17, a membrane-bound enzyme, that cleaves 
L-selectin on the surface of T cells in circulation. Cleavage of L-selectin hinders 
migration of naïve T cells into the lymph nodes and inflamed area limiting their 
ability to be activated 87,88,97,127. Outside of ADAM17, high surface expression of 
PD-L1 can directly initiate T cell exhaustion/apoptosis. Ligation of the PD-1 
receptor on the surface of T cells promotes phosphorylation of SHP-2 which 
inhibits downstream signaling events required for T cell growth, activation, 
survival, and effector functions 87,88,97. It should be noted that MDSC were found 
to exhibit suppressive effects on leukocytes other than T cells including PMN, 
Macrophages, and NK cells. MDSC have also been shown to induce polarization 
of immunosuppressive leukocytes such as regulatory T cells, M2 macrophages, 
and proinflammatory T helper17 (TH17) cells 88,99,103,128-130.   
1.2.3.5 Potential roles for MDSC in ulcerative colitis 
Multiple papers have reported the presence of MDSC in the blood and spleens of 
chronically inflamed humans and mice 76,96. MDSC were found to alleviate 
symptoms in animal models of rheumatoid arthritis and experimental 
autoimmune encephalomyelitis (EAE) 131-136. MDSC have also been observed in 
the blood, spleens, and colons of ulcerative colitis patients and mice models 
95,137. Initially, MDSC were thought to play an immunosuppressive role in colitis, 
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but since then their role has become controversial as recent studies have 
suggested that it can contribute to proinflammatory responses.   
On one hand, adoptive transfer of MDSC to colitis mice reduced inflammation 
and facilitated colonic mucosal healing. This was also observed in TNBS-induced 
colitis mice, where adoptive transfer of colitis expanded MDSC significantly 
suppressed inflammation and down-regulated cytokine production of IL-17, 
TNF-α, and IFN-γ in the colonic mucosa 138,139. G-MDSC expanded from healthy 
immature myeloid leukocytes and transferred into colitis mice increased their 
survival rate and decreased injury scores, myeloperoxidase activities, and IL-6 
levels 140. Taken together, these findings suggest a protective role for MDSC in 
intestinal inflammation.  
 
On the other hand, there is evidence that these cells can switch to an 
inflammatory phenotype under colitis conditions. Specifically, G-MDSC- like 
cells in the colon of mice with colitis gained antigen presenting cells (APC) 
functions, induced T cell activation, and pro-inflammatory cytokine production 
54,96. Furthermore, MDSC mediated polarization of CD4 T cells into Th17 and 
subsequent production of IL-17 has been recorded in chronic colitis patients and 
mice models. High numbers of TH17 cells in the intestine and elevated IL-17 
expression in the serum has been associated with colitis severity and progression 
54,141,142. The controversial role of MDSC could partially be contributed to the 
production of IL-17, as articles have demonstrated both a pathogenic and 
protective role of IL-17 in intestinal inflammation 143,144. Understanding the role 
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of MDSC during post-acute/chronic colitis is important for determining their 
therapeutic potential. 
1.2.4 The controversial role of IL-17 in ulcerative colitis  
1.2.4.1 Production of IL-17 by Th17 cells  
IL-17 is a proinflammatory cytokine that is predominantly secreted by TH17 
145,146. TH17 cells are a distinct subset of CD4+ effector cells initially 
characterized by their expression of IL-17F. Since then, TH17 cells have also 
been found to secrete IL-21, IL-22, GM-CSF, IL-8, and IL-10. In healthy 
individuals, differentiation of CD4+ T cells into the TH17 phenotype is 
dependent upon stimulation with IL-1β, IL-6, IL-23, and TGF-β 147-149. However, 
under chronic colitis conditions, several factors have been found to induce their 
polarization.  
 
These cells are important for maintaining mucosal immunity homeostasis. 
Under healthy conditions, most of the body’s TH17 cells are found in the 
intestinal lamina propria. Here, they secrete IL-17 to induce production of 
intestinal antimicrobial proteins crucial for regulating commensal bacteria 
tolerance 150,151. Additionally, IL-17 secreted in the intestinal lamina propria 
facilitates epithelial cell repair and is important for maintenance of tight 
epithelial cell junctions 152,153. The signaling events initiated by IL-17 ligation of 
its receptor are required for host immune defense.   
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1.2.4.2 IL-17 receptor activation and signaling  
 The IL-17 receptor is widely expressed on cells throughout the body, but the 
strongest responses occur in PMN, fibroblast, epithelial cells, endothelial cells, 
macrophages, and dendritic cells 154-156. Signal transduction through the IL-17A 
receptor (IL-17R) requires 1) homodimers of IL-17A or heterodimers of IL-17A 
and IL-17F binding to the receptor and 2) recruitment of the IL-17RC subunit to 
the IL-17RA subunit after ligand binding 157,158. IL-17 induced signal 
transduction induces activation of multiple pro-inflammatory pathways. 
However, due to IL-17RAs lack of homology to other well-described receptors, its 
mechanism of signal transduction is still under investigation.   
 
IL-17 signaling is shown to activate the nuclear factor- κB (NF-κB) pathway, and 
this action is facilitated by recruitment of the ACT1 adaptor protein. Once 
recruited, ACT 1 binds TRAF6 and 3, which complexes with TAK1. TAK1 
phosphorylates the inhibitor of NF-κB (IκB) thereby allowing the subunits of 
NF-κB to translocate to the nucleus and target genes that regulate migration, 
proliferation, and cytokine/chemokine production159,160.  Studies show that IL-17 
also induces activation of multiple MAPKs. However, the key role of IL-17 
activated MAPK is suggested to be regulation of mRNA transcript stability. 
MAPK phosphorylates destabilizing proteins that act on IL-17 target genes. 
Phosphorylation of these proteins inhibits their ability to recruit the degradative 
machinery, in turn increasing the concentration of target mRNAs 161,162.   
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Transcription factor C/EBPβ is activated by IL-17, as well. Its activation is 
initiated upon phosphorylation by ERK and after one hour of IL-17 stimulation, 
C/EBPβ is phosphorylated again at an alternative site by glycogen synthase 
kinase 3β (GSK3β). The purpose of this dual phosphorylation is to downregulate 
transcriptional effects C/EBPβ. The promoters of IL-17’s target genes are 
enriched for C/EBP- binding elements. Specifically, activation of pro-
inflammatory IL-6 is dependent on its binding 162-164. Based on this information, 
it has been suggested that the IL-17 mediated-sequential phosphorylation of 
C/EBPβ plays a role in the dynamic regulation of the inflammatory response.  
1.2.4.3 IL-17s contribution to ulcerative colitis pathology  
IL-17 is a potent regulator of host immune responses. The overexpression of this 
cytokine has also been identified as one of the major contributors to chronic 
inflammatory pathology 1,63,154,165,166. IL-17 is significantly elevated in the 
inflamed intestinal mucosa during colitis. IL-17 is the predominant cytokine in 
the serum, which suggests the ability to systemically regulate inflammatory 
processes. Expansion of TH17 cells in the inflamed lamina propria of the colon 
has also been documented 149,167.  
 
Like MDSC, the role of IL-17 in colitis pathology is controversial.  Some studies 
argue for a pathogenic role of IL-17 in colitis, as it triggers release of soluble 
factors such as CXCL1, CXCL8, and Il-6. These factors activate and recruit PMN, 
T cells, and NK cells, whose accumulation in the colon has been tightly 
correlated with colitis disease progression 145,168.  Induction of colitis in IL-17 
knockout mice yielded no inflammation.  In another study, antibody-mediated 
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neutralization of IL-17 in colitis mice led to aggravation of the disease condition 
156,169,170.  These findings indicate that IL-17 is required for inflammation 
initiation but may also play a role in its resolution.   
1.3 Significance   
In this study, ulcerative colitis is primarily used a model to study regulation of 
PMN infiltration and response during chronic inflammation. Indeed, this 
research is significant because it will provide further insight into the 
mechanisms governing post-acute/chronic colitis progression. Colitis pathology 
is intricate and multifactorial. Ulcerative colitis is a chronic, incurable disease 
that affects roughly 900,000 Americans. This disease is most prevalent in 
developed countries, with the highest incidence rates reported in Denmark, 
Iceland, and the United States. An estimated 38,000 people in the U.S. are 
diagnosed with colitis each year. The financial burden of IBD in the U.S. is more 
than 30 million dollars, while colitis alone has been shown to cost the 
government about $15,000 per person annually 58,66. Hence, there is a dire need 
to understand the mechanisms underlying colitis. Understanding these 
processes will be instrumental in developing strategies needed for the control 
and prevention of this disease.  
 
Clinical therapeutic options include steroids, antibiotics, and biologicals. 
Steroidal medicines such as prednisone, are used to decrease inflammation 
either at the intestinal wall or by inhibiting the body’s ability to mount and 
maintain the inflammatory response. Medicines such as these are useful for 
treating temporary flare-ups, but because of their capacity to limit the 
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inflammatory response, long-term use of steroids can lead to subsequent 
infections 56,171-173. Antibiotics slightly benefit patients with Crohn’s disease. 
However, there is no significant scientific evidence to support antibiotic 
treatment of ulcerative colitis 56,58,172,173.  Recently, biologicals have become a 
popular course of therapy for colitis patients. Infliximab and its counterparts 
target the pro-inflammatory tumor necrosis factor (TNF) pathway by binding 
with high avidity to both soluble and transmembrane forms of the protein. This 
binding prevents TNF interaction with TNF receptors on the surface of pro-
inflammatory immune cells, which decreases cytokine secretion and induces 
apoptosis of these cells. Unfortunately, there is a high rate of reduced 
responsiveness to these drugs 58,172,173.  
 
The lack of satisfactory therapeutic options creates an urgent need for effective 
curative medical treatments. The research conducted expanded our knowledge of 
both PMN and MDSC regulation in the BM of chronically inflamed mice. 
Furthermore, it suggested a potential anti-inflammatory role for BM MDSC in 
post-acute colitis.  Understanding the underlying mechanisms behind their 
reprogramming and expansion will enhance the potential of MDSC to be used as 
a treatment or target, which can provide an effective alternative to current 
options.   
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1.4 Murine Disease Models 
1.4.1 DSS colitis-to-recovery 
A variety of animal models have been developed to investigate the pathogenesis 
of human ulcerative colitis. No single model can completely recapitulate the 
functional, histopathological, and immunological components of human disease. 
However, the collective data obtained from these animal models have helped to 
elucidate the mechanisms of ulcerative colitis disease progression 174,175. The 
most commonly used murine model of colitis employs dextran sodium sulfate 
(DSS), a heparin-like polysaccharide, that acts as a colitogenic agent to induce 
epithelial damage. Due to the rapid rate of induction, reproducibility, and 
simplicity of this model it is widely used in colitis research 176,177. In relation to 
our research specifically, DSS-induced colitis has been shown to induce PMN 
infiltration into the lamina propria and submucosa and trigger the inflammatory 
response. Progression of treatment to the chronic stage is marked by trans-
epithelial migration of PMN, which causes the cryptitis and crypt abscesses 
frequently found in human disease 178.  
 
Infiltration of myeloid leukocytes perpetuates the epithelial damage initiated by 
the chemical DSS. Many of the inflammatory mediators regulating PMN 
infiltration and response become elevated in the tissues and serum of this 
treatment model. In the acute colitis model, (1-2%, given 5-7 d) expression of 
TNFα, IL-6, IL-1β, and IL-8 in tissues is significantly increased. Chronic DSS-
induced colitis (2-5%, given 9-14 d or in repeated cycles) leads to polarization of 
TH2 cells, culminating in decreased expression of proinflammatory cytokine 
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TNF-α and increased levels of IL-10, Il-4, IL-6, and IFN-γ 179-182. Furthermore, 
high expression of IL-17 has been reported in the tissue and serum of DSS- 
induced colitis mice at the post-acute/chronic stage of treatment, which 
resembles human ulcerative colitis 1,140,179. According to our studies and studies 
by others, IL-17 can induce an exaggerated PMN response during DSS colitis 
through at least two mechanisms, 1) promoting granulopoiesis, thereby 
replenishing the PMN supply, and 2) potentiating PMN response causing 
enhanced PMN chemotaxis, ROS production, etc. 148,156,168.  
 
Mice can be made to morphologically and symptomatically model acute and 
chronic colitis, respectively, by modifying the concentration, duration, and 
frequency of treatment with DSS. The molecular weight of DSS is crucial for 
colitis induction and progression. Most protocols use 40-50 kDa of DSS to 
achieve both an acute and chronic inflammatory state in the colon, where 
disease severity can be controlled by changing the conditions mentioned above 
178,181-183. In addition to molecular weight, mice strain, sex, and gut microbial 
environment all contribute to disease development 184,185. To induce colitis, DSS 
is administered to mice in tissue culture grade water. While the exact method of 
DSS induction is still being debated, the common theory is that it disrupts the 
intestinal epithelial monolayer lining, which in turn activates the inflammatory 
response. The sulfated polysaccharide does not directly induce intestinal 
inflammation, but instead acts as a chemical toxin to damage colonic epithelium 
causing epithelial cell injury 186-188.  
25 
1.4.1.1 DSS disrupts mucosal barrier function  
Administration of DSS, leads to weakening of the distal colon epithelial lining 
resulting in entry of luminal commensal bacteria and associated antigens into 
the mucosa. This allows potentially pathogenic intestinal components (e.g., 
bacteria and their products) into the lamina propria174,186. The mechanism of 
how DSS disrupts the distal colon is still under investigation. Many studies 
report that, like ulcerative colitis patients, mice treated with DSS exhibit altered 
tight junction complexes coupled with subsequent increases in colonic 
permeability. Therefore, the increase in colonic mucosal permeability is 
considered the first event, followed by breaches in the mucosa barrier that allow 
the influx of inflammatory cells into the intestinal mucosa 189,190. Additionally, 
some studies suggest that dextran sulfate inhibits ribonuclease action, but the 
mechanism of how DSS penetrates the cell is also unclear 191,192. Recent studies 
indicate that DSS combines with medium-chain-length fatty acids that are 
present in the colonic lumen to form nano-lipocomplexes, which can fuse with 
colonocyte membranes and further activate downstream inflammatory signaling 
pathways inside the cytoplasm 193. 
1.4.1.2 Mucin in DSS-induced colitis pathology 
Intestinal mucus is crucial for efficient barrier function, as it contains 
proteins required for epithelial barrier integrity. The colon mucosa is comprised 
of both secreted and membrane bound forms of glycoproteins named mucins 
194,195. Secreted gel-forming mucins protect the epithelium from commensal 
microbiota in the colon by covering it to provide a mucosal barrier. As 
membrane bound forms of mucin possess transmembrane regions, they have 
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been implicated in cell signaling, adhesion, and growth. Additionally, membrane 
bound mucin have been found to modulate the immune response by activating 
downstream signaling pathways that activate leukocytes 196,197.  
 
These proteins become altered in patients with colonic inflammation and 
contribute to dysregulation of barrier functions. In MUC2 (the primary mucin 
present in the colon) knockout mice, decreases in mucus gel thickness occurred 
at the same time mice begin to display symptoms of DSS treatment. Studies 
show that post-translational modifications are important for MUC2 function as 
well. During acute DSS-induced colitis, decreased sulfation of MUC2 results in a 
failure to control inflammation, even though its expression is temporarily 
increased. Changes to the glycosylation of these proteins impair MUC2 
synthesis, which weakens barrier integrity to increase susceptibility to DSS 
treatment 198. Conversely, deletion of transmembrane MUC 1 and 4 proteins 
resulted in protection of the intestinal epithelium and resistance to DSS-induced 
colitis 194,196,197. Altogether the findings discussed here suggest that DSS 
treatment also modifies the mucosal barrier structure to promote disease 
development.  
1.4.1.3 DSS effect on commensal bacteria 
Research investigating the role of gut commensal microbiota in the pathogenesis 
of intestinal inflammation has become popular in recent years. Many studies 
demonstrate changes to the microbiota of DSS mice, as early as the acute phase, 
at 3 days (3d), like those in colitis patients 199,200. Specifically, the anti-
inflammatory populations of bacteria that regulate homeostasis in healthy 
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colons, such as Bacteroidetes, Prevotella, Clostridium, and Lactobacillus were 
reduced in mice treated with DSS. This decrease was coupled with expansion of 
pro-inflammatory microbial genera in the colon. Compositional changes to the 
microbiome further promote pathogenesis of colitis, especially in the case of 
Faecalibacterium prausnitzii. Diminishment of F. prausnitzii, enhances 
synthesis of proinflammatory cytokines in the colon through activation of the 
NF-κB pathway and induction of IL-8 180,201,202. Clearly, murine DSS treatment 
mimics the effect of human ulcerative colitis on the microbiota. Interestingly, in 
studies where DSS was removed, populations of healthy colonic commensal 
bacteria were rapidly restored 180,189. Post-treatment, anti-inflammatory 
intestinal microbiota became abundant, even when compared to healthy 
animals. Nevertheless, the various methods used by DSS to induce colitis 
collectively promote development of colonic inflammation, that resembles 
ulcerative colitis in humans. These underlying mechanisms are 
directly/indirectly associated with manifestation of colitis symptoms including 
significant weight loss, diarrhea, bloody stool, reduced colon length, loss of 
colon epithelial tissue, and crypt architecture disruption 66.  
 
We created a 2% DSS-induced colitis-to-recovery mice model to investigate 
leukocyte response under acute, post-acute/chronic, and resolution conditions 
(Fig. 1.2). To do this, mice received 2% DSS dissolved in tissue culture grade 
water 1,203. Mice were treated for 9 days (9d) consecutively to induce chronic 
colitis and then allowed to recover for ~21 days (21d). The symptoms mentioned 
above were monitored to follow disease progression. Indeed, we show that 
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colitis-to-recovery mice exhibit body weight loss, colon tissue loss, and bloody 
diarrhea associated with the inflammatory response elicited by DSS. 
Furthermore, high expression of IL-17 in the serum of our mice resembled what 
is seen in the human condition. Ultimately, DSS induction of colitis is a simple 
and controllable animal model to study PMN infiltration and response, due to its 
similarity to human ulcerative colitis.  
 
 
 
 
 
 
1.4.2 Zymosan-induced peritonitis as a PMN response assay 
Zymosan-induced peritonitis is a robust model of self-resolving acute 
inflammation. Intraperitoneal injection of zymosan increases vascular 
permeability and transiently activates the inflammatory reaction. The response 
elicited by treatment mimics characteristics of acute inflammation including 
pain, synthesis of pro-inflammatory mediators, and leukocyte infiltration 204-207. 
While zymosan has been shown to activate macrophages and natural killer (NK) 
Figure 1.2: Scheme of DSS-induced colitis–recovery model in C57BL/6 mice.  
Mice (~20g) were treated with 2% DSS in drinking water for 9 d, followed by 21 
d of pure water. Indicators of disease progression and recovery were then 
monitored. 
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cells, its ability to recruit PMN in to the peritoneum within 4-6 hours makes it 
an excellent method to assay their response 1. Despite this, development of 
peritonitis is dependent upon secretion of proinflammatory mediators by 
activated peritoneal macrophages.  PMN and macrophages also play a 
collaborative role during the end of inflammation, as PMN apoptosis and 
subsequent efficient clearance by macrophages is required for resolution of this 
model 10,208-210.   
 
Zymosan is a component of the yeast cell wall that is primarily composed of β-
glucans or polymers of D-glucose. These β-glucans along with other components 
of zymosan including mannans, chitin, and lipids have been shown to activate 
various pattern recognition receptors (PRR) on the surface of peritoneal 
macrophages 207,211. Specifically, β-glucan ligation of dectin-1 receptor and TLR2 
leads to production of histamine and leukotrienes that increase vascular 
permeability, thereby promoting leukocyte infiltration 204,205,208,211,212. Ligation 
of TLR2 on peritoneal macrophages has also been shown to activate 
transcription factor NF-κB and induce secretion of pro-inflammatory 
cytokines/chemokines TNF-α, IL-8, and ββ 208,212,213. As a result, macrophages 
are thought to orchestrate inflammation onset in this animal model through 
selective secretion of inflammatory mediators.  
 
For my research, adoptive transfer experiments were coupled with zymosan-
induced peritonitis to assay the response of BM myeloid leukocytes under 
chronic inflammatory conditions. Myeloid leukocytes isolated from the BM of 
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mice treated with 2% DSS were fluorescently labeled and intravenously injected 
into healthy donor mice. Following this, 0.25mg of zymosan was injected into 
the peritoneal cavity to induce infiltration of the transferred cells. It was found 
that ~80% of myeloid leukocytes from chronically inflamed mice infiltrated the 
peritoneum by 2.5 hrs compared to healthy myeloid leukocytes, which arrive 
within 4-6 hrs. These data suggest that BM myeloid populations demonstrate 
enhanced responses during chronic inflammation.  Taken together, these studies 
confirm the value of zymosan-induced peritonitis as both a self-resolving model 
of acute inflammation and PMN response assay.   
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2 CYTOKINE REGULATION OF MYELOID LEUKOCYTES UNDER 
INFLAMMATORY CONDITIONS 
2.1 Chapter Introduction  
Cytokines and soluble mediators are important for homeostasis and proper 
balance of immune function. However, increased or continuous expression of 
these factors has been implicated in the pathogenesis of both clinical and 
experimental models of ulcerative colitis 2,64,179. During intestinal inflammation, 
a wide variety of cytokines, chemokines, and other pro-inflammatory factors are 
produced by T cells, macrophages, and neutrophils. Studies show that increased 
polarization of Th1 cells during intestinal inflammation leads to elevated levels 
of pro-inflammatory cytokines such as TNF-α and IFN-γ, which have been 
identified as major contributors to ulcerative colitis progression. Pro-
inflammatory mediators released during chronic inflammation also control 
leukocyte activation, recruitment, and effector functions 64,214. Therefore, the 
abundance of factors such as TNF-α, IL-6, IFN-γ, GM-CSF, IL-8, and IL-17 in 
the inflamed colon and serum of colitis patients promotes the continuous 
infiltration of inflammatory cells and their enhanced response, all of which 
contribute to disease pathology. Although several articles have investigated 
cytokine regulation of leukocyte responses during chronic colitis, the effect of 
pro-inflammatory mediators on the myeloid population is still unclear. This 
chapter focuses on reviewing the literature on mechanisms underlying cytokine 
regulation of myeloid leukocyte recruitment, infiltration, and response during 
ulcerative colitis.  
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2.2 Pro-inflammatory Regulators of PMN Response During Colitis  
Pro-inflammatory cytokines regulate PMN recruitment and response by binding 
their respective receptors on the cell surface and initiating signal transduction, 
which has been shown to predominantly activate transcription factors 
MAPK/extracellular signal-regulated kinase (MEK-ERK), MAPK kinase 3/6 
(MKK3/6-p38 MAPK), phosphatidylinositol 3-kinase (PI3K), and NF-κB. The 
primary pro-inflammatory cytokines shown to rapidly activate these pathways 
are G-CSF, GM-CSF, TNF-α, and interleukin-1β 18,215,216. It should be noted that 
IL-6 and IL-17 have also been identified as major regulators of PMN responses, 
but this will be further discussed in a separate section. While these factors have 
been shown to regulate multiple cellular processes including ROS production, 
adhesion, cytoskeletal remodeling, migration, and apoptosis, the effect of each 
depends on the activating cytokines 217. Pro-inflammatory cytokines act 
collaboratively to support the host immune response, but under ulcerative colitis 
conditions the excessive stimulation of PMN significantly contributes to disease 
progression.  
2.2.1 Cytokine regulation of PMN migration 
Multiple pro-inflammatory factors have been found to mediate PMN recruitment 
and migration during inflammation. G-CSF, GM-CSF, and TNF-α especially have 
been shown to regulate PMN adhesion and chemotaxis. In ulcerative colitis 
patients and animal models, G-CSF promoted enhanced PMN motility that 
contributed not only to PMN infiltration of the colon but also to their rapid 
mobilization from the bone marrow (BM). Additionally, GM-CSF and TNF-α 
were found to induce β2 integrin–dependent adherence, suggesting a role in 
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transmigration 18,218,219. When PMN arrive in the inflamed area, they use 
chemotaxis to locate and uptake the insult. To do this, they rapidly polymerize 
and depolymerize actin filaments to create the leading edge or lamellipodia, 
which is required for crawling. In vivo experiments revealed that stimulation of 
PMN with G-CSF results in protrusion of lamellipodia. Furthermore, activation 
of human PMN with G-CSF, GM-CSF, or TNF-α induced actin depolymerization 
thereby mediating cytoskeletal remodeling 18,217-219.    
2.2.2 Control of PMN effector functions by inflammatory mediators 
Release of ROS is a major effector function of PMN that is crucial for removal of 
pathogen. In ulcerative colitis, enhanced ROS production by PMN contributes to 
tissue damage in the intestines. Activation of the MEK-ERK and MKK3/6-p38 
MAPK pathways by GM-CSF, TNF-α, and IL-1β have been implicated in the 
production of ROS via activation of NADPH oxidase 18,215. These findings 
indicate that GM-CSF, TNF-α, and IL-1β contribute to ROS induced tissue 
damage during intestinal inflammation. Enhanced ROS production coincides 
with decreased apoptosis in PMN of humans and mice with chronic colitis. Pro-
longed PMN life span in the colon is a driving factor of ulcerative colitis 
pathology. Delayed PMN apoptosis may be due to cytokine regulation of 
intracellular apoptotic molecules. IFN-γ and TNF-α activation of NF-κB was 
found to have an anti-apoptotic effect in human PMN. G-CSF was also found to 
induce expression of inhibitor of apoptosis protein cIAP2, which prevents 
translocation of pro-apoptotic Bcl-2 family proteins  70,71,220. The studies 
discussed clearly indicate the importance of pro-inflammatory cytokines in the 
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regulation of PMN infiltration and responses and how their presence contributes 
to intestinal inflammation. 
2.3 IL-17 Regulation of the Bone Marrow Myeloid Compartment in 
Ulcerative Colitis  
IL-17 is significantly elevated in the serum and inflamed mucosa of ulcerative 
colitis patients and mice models. As shown in figure 2.1, the primary cytokine 
present in the serum of DSS colitis mice is IL-17, suggesting its ability to 
systematically regulate the inflammatory response 149,156.  In particular, IL-17’s 
regulation of PMN differentiation, activation, and recruitment from the BM 
indicates that it is a crucial regulator of inflammatory responses 155,159,161-164,166. 
IL-17’s ability to induce production of other pro-inflammatory factors such as 
IL-6, GM-CSF, TNF-α, IL-1β, IL-8,CXCL1 and G-CSF in leukocytes, especially 
PMN has been identified as a major contributor to ulcerative colitis pathology 
1,149,154. IL-17 has also been shown to regulate PMN effector functions through 
induction of nitric oxide, MMPs, β-defensin, and etc. 1,143,146,156,217,221 . Under 
chronic colitis conditions, IL-17 induced retinoic-acid-related orphan receptor 
C1 (RORC1) expression was found to drive emergency myelopoiesis via 
activation of transcription factors NF-κB, P38/MAPK, C/EBPβ (CCAAT-
enhancer-binding protein-β) and SOCS3 (suppressor of cytokine signaling 3) 221-
223. These findings indicate the deleterious effect of IL-17 in ulcerative colitis 
pathology. However, induction of colitis in IL-17 knockout mice yielded no 
intestinal inflammation, while antibody-mediated neutralization of IL-17 in 
colitis mice led to the aggravation of the disease 143,144,169,221,224. Therefore, these 
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findings suggest that IL-17 promotes colitis disease progression, it may also 
demonstrate suppressive effects. 
 
 
 
 
 
 
 
 
 
 
 
2.3.1 The dynamic relationship between IL-17 and MDSC during 
inflammation resolution. 
Several studies have examined the direct and indirect contributions of IL-17 to 
the resolution of intestinal inflammation. In a clinical setting, ulcerative colitis 
patients treated with antibodies against IL-17 exacerbated disease symptoms, 
which implies a more complex role for IL-17 in colitis than originally thought 
143,144,169. In this study, IL-17 was still elevated in the serum of DSS-induced 
Figure 2.1: Expression of IL-17A during DSS-induced colitis in mice.  
According to this figure, IL-17A is highly expressed at the post-acute stage of 
DSS-induced colitis in mice. (Bian et al., 2012)   
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colitis-to-recovery mice, albeit at lower levels, during inflammation resolution 
when expansion of G-MDSC was observed. MDSC are a population of immature 
myeloid cells arrested at various stages of differentiation and as such can be 
induced by the same factors as mature PMN. IL-6 and GM-CSF, specifically, 
have been shown to contribute to their induction in cancer and chronic 
inflammation. Recently, other mediators have been found to induce generations 
of MDSC in various models of chronic inflammation 81,102,103,116,135. Despite this, 
all studies suggest induction of MDSC requires at least two cytokines.   
 
IL-17 regulates production and secretion of both IL-6 and GM-CSF under 
chronic inflammatory conditions. Furthermore, it has been shown to induce 
secretion of other MDSC stimulatory factors such as G-CSF, IL-4, and IL-10 
95,116,138,142,225. Our research demonstrates that immature myeloid leukocytes 
collected from the BM of mice at the post-acute phase of colitis treatment 
display characteristics of G-MDSC. As IL-17 is the primary cytokine systemically 
present in our model at the time of MDSC expansion, it is likely that it may play 
a direct/indirect role in regulating MDSC under colitis conditions. IL-17’s role in 
the development of MDSC has yet to be studied in chronic inflammation. 
However, recent studies indicate that IL-17 not only promotes expansion of 
MDSC, but also inhibits their apoptosis in animal models of colorectal cancer 
and Lewis lung carcinoma 226,227. On the other hand, MDSC were found to effect 
TH17 cells as they inhibited TH1 responses while enhancing TH17 generation 
and inducing IL-17 production in a murine model of chronic colitis 54,141. Taken 
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together, these findings suggest that there is a dynamic relationship between IL-
17 and MDSC in chronic intestinal inflammation. 
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3.1 Chapter Introduction 
Myeloid leukocyte recruitment and responses are essential for the innate 
immune response. When tissue injury, infection, or trauma occurs various cells 
in the affected area including damaged epithelial cells and tissue-resident 
macrophages secrete a variety of pro-inflammatory cytokines and chemokines 
such as IFN-γ, IL-8, CXCL1, TNF-α, IL-6, GM-CSF and IL-17 3,32,61,204.  These 
mediators were found to orchestrate the inflammatory response primarily 
through activation, recruitment, and regulation of immune cells effector 
functions, especially in polymorphonuclear leukocytes (PMN). The pro-
inflammatory mediators also alter the vasculature and microenvironment at the 
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site of insult to promote PMN infiltration. PMN are the first leukocytes to arrive 
at the site of inflammation and their responses are required to establish the 
inflammatory response 1,5.   
 
PMN are mature granulocytes that express myeloid specific markers 
CD11b+Ly6GhiLy6C+.  They comprise~50-60% of total circulating leukocytes in 
healthy individuals. Although the life span of PMN in circulation varies in the 
literature, they are considered short lived when compared to other leukocytes 
such as T lymphocytes, B lymphocytes, and macrophages.  To maintain their 
high numbers in circulation, an average of 1.5 ×1011 PMN are generated in the 
bone marrow (BM) per day under healthy conditions 4,6 . Inflammation induces 
recruitment of circulating PMN and mobilizes PMN from the BM to infiltrate the 
inflamed area. 
 
PMN become completely activated upon migration into the inflamed tissues, 
resulting in secretion of anti-microbial proteins and cytotoxic enzymes including 
myeloperoxidase (MPO), neutrophil elastase (NE), matrix metalloproteases 
(MMPs), reactive oxygen species (ROS), and nitric oxide (NO) 15,42-48,213. PMN 
also uptake and degrade damaged cells and pathogen using phagocytosis and 
generate neutrophil extracellular traps (NETS), which are web like structures of 
chromatin fibers that contain granular proteins such as NE, MPO, and ROS to 
immobilize and degrade pathogen extracellularly before phagocytosis. 
Additionally, PMN secretion of cytokines/ chemokines perpetuates inflammation 
by recruiting macrophages, T cells, and B cells needed for the adaptive immune 
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response 4,17,43,53,75. Studies show that apoptosis not only decreases expression of 
inflammatory mediators in the tissues, but also polarizes suppressive cell types 
that down regulate inflammation, thereby promoting resolution 18,20,70-72. In the 
acute inflammatory response, clearance of pathogen and PMN apoptosis is 
followed by inflammation resolution, tissue repair, and a return to homeostasis.  
 
Failure to resolve the acute immune response results in post-acute or chronic 
inflammation. A combination of genetic susceptibility, immune system 
dysregulation, and microenvironmental factors are thought to initiate chronic 
inflammation 4,56,59-61,178. As non-specific PMN responses contribute to 
inflammatory pathology, they are thought to promote the development and 
progression of chronic inflammation. Specifically, PMN infiltration and response 
has been correlated with disease severity in several chronic inflammatory 
diseases including Crohn’s disease, ulcerative colitis, and rheumatoid arthritis 
11,12,43,228. Therefore, understanding how these leukocytes are regulated under 
inflammatory conditions could provide novel therapeutic options for treatment 
of the above conditions.   
 
In our previous study, a dextran sodium sulfate (DSS)-induced colitis model was 
used to investigate PMN response during chronic inflammation 1. Briefly, mice 
were given 2% DSS in water continuously to create an active inflammatory state 
in the intestines. Following this zymosan-induced peritonitis, a model of acute 
inflammation, was used as an in vivo response assay to examine PMN 
infiltration under chronic inflammatory conditions. It was revealed PMN from 
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colitis mice infiltrated the peritoneum in less than 2.5 hours when compared to 
healthy PMN that normally arrive in the peritoneum 4-6 hr after zymosan 
injection. Furthermore, adoptive transfer of BM leukocytes from chronically 
inflamed mice to healthy mice showed that the BM leukocytes become altered 1 
This finding suggested that a reprogramming event occurs in the BM of mice 
with chronic inflammation, contributing directly to enhanced infiltration during 
peritonitis.  
 
Although this study provided crucial information regarding the regulation of 
PMN during chronic inflammation, some questions remain unanswered. If there 
is indeed a reprogramming event that occurs in the BM myeloid compartment 
under chronic inflammatory conditions, what is the functional significance of 
these alterations? Additionally, we are interested in how this population changes 
as inflammation is resolved. To investigate these issues, a murine DSS- induced 
colitis-to-recovery model was created. Mice were treated with DSS in water for 
9d, which was followed by removal of the chemical insult to allow inflammation 
resolution. BM, spleens, colons, and blood were collected from treatment mice 
for analysis post euthanasia at multiple time points.  
 
Analysis of Percoll density gradient separated BM myeloid leukocytes revealed 
that the mature PMN population progressively decreases during the post-acute 
phase of treatment. Decreased numbers of PMN were likely a result of their 
mobilization into circulation. Interestingly, the immature myeloid leukocyte 
population transiently increased during the same time frame. Phenotypic and 
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functional analysis of both immature and mature BM myeloid leukocytes 
demonstrated that PMN isolated from the BM become functionally primed, 
exhibiting enhanced ROS production and infiltration in adoptive transfer 
experiments. More importantly, it was shown that chronic colitis induced 
expansion of immunosuppressive granulocytes with increased expression of 
myeloid migratory receptor CXCR2.   
 
These immature granulocytes displayed enhanced ROS production and 
migratory abilities like mature PMN, but also demonstrated characteristics of 
myeloid derived suppressor cells as they expressed ARG-1 and gained the ability 
to potently suppress T cell proliferation. Release of immature myeloid 
leukocytes from the BM is common during chronic inflammation, due to 
emergency myelopoiesis, a process where PMN precursors are released from the 
BM to satisfy the increased need for PMN. However, these cells are generally 
pro-inflammatory and do not possess suppressive functions77,223,229. 
Furthermore, ARG-1+ immature granulocytes were identified in spleens and 
colons of DSS treated mice during inflammation resolution. Taken together, 
these findings suggest that reprogramming of the myeloid compartment 
produces both functionally primed PMN that accelerate pathogen clearance 
toward resolution and immunosuppressive granulocytes that suppress T cell 
responses beginning at the post-acute/chronic phase of DSS treatment and 
lasting throughout inflammation recovery.   
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3.2 Materials and Methods  
3.2.1 Murine DSS-induced colitis-to-recovery models:  
C57BL/6 mice (6-10 weeks old, 18-22 g) were obtained from The Jackson 
Laboratory (Bar Harbor, ME) and were housed in a pathogen-free facility with 
access to food and water. To induce colitis, 2% dextran sodium sulfate (DSS, MP 
Biomedicals) was dissolved in pure water and given to mice for drinking. Mice 
were treated with DSS for 9 consecutive days, followed by up to 21 days (21d) of 
non-DSS treated drinking water to allow for recovery.  
 
Mice were examined daily to assess the level of stress, onset of colitis symptoms, 
and recovery from inflammation. The disease activity index (DAI) was calculated 
using an average of three criteria: 1) percentage body weight loss (0, none; 1, 1-
5%; 2, 5-10%; 3, 10-15%; 4, >15%), 2) stool consistency (0, solid stool; 2, loose 
stool; 4, diarrhea), and 3) presence of blood in stool (0, negative; 2, positive; 4, 
gross bleeding) as shown in previous colitis studies 1,203. Serum, spleen, colon, 
and BM were collected post euthanasia every three days (0, 3, 6, 9, 12, 15, 18, 21, 
24, 27, 30d) for analyses. 
3.2.2 Measurement of serum cytokines:  
Serum was isolated from whole blood by low speed centrifugation. Cytokine 
levels in the serum were assayed using the standard sandwich ELISA. Serum 
samples were incubated (2 h, 25°C) in a 96-well plate coated with capture 
antibodies against IL-6, IL-17, TNF-α, IFN-γ, GM-CSF, IL-10, IL-4, TGF-β, IL-
22. After washing, the wells were incubated with biotinylated detection 
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antibodies and HRP-conjugated streptavidin, followed by color development 
using OPD. Data was analyzed using SoftMax Pro microplate data software. 
Purified and biotinylated antibodies against all cytokines were purchased from 
BD Biosciences or BioLegend. Recombinant cytokines used as standards were 
purchased from PeproTech.    
3.2.3 Percoll gradients separation of bone marrow leukocytes: 
Prior to preparing density gradients, Percoll (Sigma) was adjusted to 150 mM 
NaCl, 325 mOsM by mixing 1-part 10× HBSS with 9-parts Percoll. Further 
dilution in HBSS (v/v) produced Percoll density solutions of 70% (1.088 g/mL), 
60% (1.076 g/mL), 50% (1.064 g/mL), and 40% (1.052 g/mL). Four-step 
discontinuous density gradients were prepared in a 15 mL tube by successively 
layering decreasing density solutions (2 mL/layer) upon one another (70, 60, 50, 
and 40%) starting with the densest placed at the bottom. To better distinguish 
density layers, some Percoll solutions were prepared in HBSS with phenol red to 
create alternating-colored density layers. Approximately 3×107 - 5×107 BM cells 
harvested from femur and tibia by flushing bone cavities followed by RBC lysis 
were placed on top of the gradients in 2 mL PBS, followed by centrifugation at 
1000 × g for 45 min in a swinging bucket rotor. This centrifugation resulted in 
cells forming three leukocyte-enriched fractions at the density-transition 
interfaces.  
 
Cells in each band were collected, washed, and counted. FACS analysis of CD11b, 
Ly6G, LY6C, and CXCR2 (antibodies from Biolegend) surface expression was 
used to identify the myeloid compartment. Further separation of Ly6G+ 
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granulocytic and Ly6Chigh monocytic leukocytes enriched in fraction III was done 
using biotin-conjugated anti-Ly6G antibody and streptavidin-conjugated 
magnetic microbeads, which positively selected granulocytes (>95% purity), 
leaving the unbound to be majorly (>85%) of Ly6Chigh monocytes. 
3.2.4 Immature myeloid cell and PMN functional assays:  
To measure ROS production, leukocytes treated with 1 μM PMA in the presence 
of 5 μM oxidation sensitive dye DCFDA (Invitrogen). After washing, DCFDA 
staining was correlated with intracellular ROS production and measured by 
Fluorescent Activated Cell Sorting (FACS). To test myeloid leukocyte response 
during chronic inflammation-to-recovery, mature PMN or immature myeloid 
cells isolated from the BM (1 × 107 each) were labeled with 5-(and-6) (((4-
chloromethyl) benzoyl) amino) tetramethyl-rhodamine [CMTMR, red] or 
carboxyfluorescein diacetate succinimidyl ester (CFSE, green) respectively, and 
administered (i.v.) into healthy C57BL/6 mice. Following intravenous myeloid 
leukocyte administration, mice immediately received injections of PMN 
activation agent zymosan (0.25 mg).  
 
3.2.5 T cell proliferation assay:  
Freshly  isolated healthy splenocytes (6 ×105 cells/mL) labeled with 
carboxyfluorescein succinimidyl ester (CFSE) were induced to proliferate in a 
96-well plate that had been immobilized with anti-CD3 antibody (1 μg/mL) in 
the presence of soluble anti-CD28 antibody (0.5 μg/mL, both from Biolegend) in 
RPMI1640 media with 10% FBS, 2 mM L-glutamine and 50 nM β-
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mercaptoethanol for 4 days (4d) (37οC, 5% CO2). To examine MDSC-mediated T 
cell inhibition, the Fraction III (Fr. III) population of leukocytes were added into 
the T-cell proliferation system at the ratio of 1:6 or 1:8 of leukocytes to 
splenocytes. T-cell proliferation was then evaluated microscopically and by FACS 
that determined CFSE intensity. 
3.2.6 Murine tissue analysis:  
To isolate cells from the spleen, spleens were emulsified in RBC lysis buffer (155 
mM NH4 Cl, 10 mM KHCO3, and 1 mM EDTA) at room temperature in 1× PBS 
and filtered through nylon mesh with a pore size diameter of 70 μm. Cells were 
collected in ice-cold 1× PBS and labeled with two combinations of fluorescence-
conjugated antibodies (anti-mouse CD4 and CD8, or CD11b, Ly6C, and Ly6G) at 
a concentration of 1g/mL. Cell populations were analyzed by FACS (LSR 
Fortessa, BD Biosciences).  
 
For histochemical staining, mouse colons were fixed in 4% paraformaldehyde, 
embedded in Neg-50 (ThermoFisher), and cut into 5–10-mm thin sections, that 
were then stained with H&E. For staining of infiltrated myeloid leukocytes and 
expression of tissue repair proteins, freshly sectioned tissues were blocked with 
5% BSA followed by staining using anti mouse PE-conjugated Ly6G, FITC-
conjugated a-SMA, PE-conjugated Ki67 Ab, and DAPI (nucleated cells). Images 
were captured using a Keyence fluorescence microscope imager.  
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3.2.7 Statistical analysis: 
Data are presented as the mean ± SEM. Statistical differences/ significance 
between data sets were assessed using the two-tailed Student's t-test for two 
groups or one-way ANOVA. Dunnett’s Multiple Comparison test was used to 
compare data means. 
3.3 Results  
3.3.1 Murine DSS-induced colitis-to-recovery model:  
In this study, we investigated the reprogramming of the BM myeloid 
compartment using a common model of PMN associated chronic inflammation, 
DSS-induced colitis.  To induce intestinal inflammation, healthy C57BL/6 mice 
20g or above were given 2% DSS in water for 9d to develop an active 
inflammatory state in the intestines. We modified the traditional DSS-induced 
colitis model by removing the chemical insult to allow for inflammation recovery 
(Fig. 3.1A). Colitis induction in mice is marked by a series of symptoms 
including significant weight loss, colon shrinkage, diarrhea, and bloody stool 
66,178,181,193.   These symptoms were used as disease prognosis markers to monitor 
disease development. Decrease in body weight (Fig. 3.1B), disease activity index 
(DAI) (Fig. 3.1C), and colon tissue loss (Fig. 3.1D) observed at the post-acute 
stage of treatment, ~9-15d, suggest that colitis was successfully established in 
mice. After removal of DSS, all markers gradually returned to baseline. It should 
be noted that colon morphology did not return to its original shape until after 
30d (Fig. 3.1D).  
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In ulcerative colitis patients, expression of IL-17 is associated with disease 
pathogenesis.  Several studies have reported that IL-17 is the primary cytokine 
elevated in the serum of DSS-induced colitis mice as well 1,138,143,144,169,170. This 
was recapitulated in our DSS colitis-to-recovery model, as serum IL-17 
expression increased to ~2 ng/ml (3-fold) at the post-acute phase. Surprisingly, 
IL-17 expression remained elevated after PMN infiltrated the intestine and did 
not return to basal level until the late in inflammation resolution (~18-30d) (Fig. 
3.1E). Comparably, other pro-inflammatory cytokines such as IL-6, IFN-γ, and 
GM-CSF showed no significant changes in the serum. 
 
Fecal lipocalin 2 (LCN-2), also known as neutrophil gelatinase-associated 
lipocalin (NGAL) in humans, has recently been identified as a biomarker for 
both active inflammation and inflammation recovery. LCN-2 is released by 
degranulating PMN during active inflammation. Recently, it was shown that 
LCN-2 is highly inducible in intestinal epithelial cells during tissue recovery. 
Apical secretion of LCN-2 in the lumen and the ability to assay its expression in 
feces suggest it acts locally during inflammation and does not get metabolized. 
Due to its stable expression in the feces of mice with intestinal inflammation, 
analysis of LCN-2 by ELISA has emerged as a non-invasive method to monitor 
colitis disease progression 73,230-234. Feces collected from colitis-to-recovery mice 
displayed elevated expression of LCN-2 at the post-acute phase of treatment. 
Furthermore, we show that its expression continues to increase during recovery, 
reaching ~5 x 103 ng/g of feces at 18d, thus confirming both the chronic 
inflammatory and recovery aspects of our model (Fig. 3.1F).  
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3.3.2 Percoll gradient separation of the BM myeloid compartment:  
Percoll density gradients were employed to determine if the BM myeloid 
population becomes altered in mice with chronic colitis. As shown in Fig. 3.2, a 
gradient centrifugation separated BM leukocytes into four density-decreasing 
fractions (Fr.) I, II, III, and IV, settled at the density 
interface of 5–40, 40–50, 50–60, and 60–70%, respectively.  For our purposes 
Fr. I and II were combined into one Fr. that contained stromal cells, fibroblast, 
and B lymphocytes (data not shown) 1,116,203,235. CD11b+ Gr-1+ myeloid 
leukocytes were enriched in Fr. III (50-60%) and IV (60-70%). Specifically, Fr. 
III was comprised of Ly6Chigh monocytes and low-density Ly6G+ granulocytes. 
Fr. IV contained mature PMN, which were LY6G+ and displayed high SSC values 
indicative of complex intracellular granular structures (Fig. 3.2B).  
 
Upon identifying and isolating our target populations, each Fr. was collected, 
counted, and expressed as a percentage of the total number of BM leukocytes. In 
0d healthy control mice, percentages of BM cells distributed in Fr. I+II, III, and 
IV were approximately 24%, 28%, and 50%, respectively. For mice at the post-
acute stage of colitis (9d), the percentage in Fr. III transiently increased to ~66% 
and did not return to baseline until late stage recovery (18d). Concomitantly, 
PMN (Fr. IV) percentage progressively decreased during active inflammation, 
likely as a result of mobilization into inflamed tissues, but recovered when 
inflammation subsided (Fig. 3.2C, Table 3.1).  
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3.3.3 Reprograming of the BM myeloid compartment during chronic 
inflammation:  
Although PMN percentages significantly decrease in the BM at the post-acute 
stage, enhanced ROS production was observed when leukocytes were activated 
with PMA (Fig. 3.3A). To test PMN response in vivo, adoptive transfer 
experiments were conducted. For these experiments, Percoll separated myeloid 
leukocytes of Fr. IV collected from mice under colitis-to-recovery treatment were 
labeled with CMTMR (red fluorescent dye). The labeled Fr. IV leukocytes were 
transferred into healthy recipient mice, that were then intraperitoneally (IP) 
injected with zymosan to induce peritonitis. Consistent with our previous 
findings, analyses of the recipient mice 2.5 h later showed that leukocytes from 
mice at the post-acute stage (9-15d) of treatment display significantly enhanced 
infiltration into the peritoneum (Fig. 3.3B). Thus, suggesting that PMN become 
functionally primed in the BM of mice with chronic colitis.  
 
Ligation of migratory receptor CXCR2 on the surface of PMN facilitates their 
release from the BM.  Traditionally, immature myeloid leukocytes express low 
levels of CXCR2 until maturation 12,22,24,25. However, it was found that chronic 
inflammation induced expression of CXCR2 in the expanded population of 
immature myeloid leukocytes (Fr. III) (Fig. 3.3C). Additionally, enhanced 
production of ROS was observed during the post-acute phase of treatment 
(Fig.3.3D). These data suggest that the immature leukocytes become effectors 
cell that can be recruited into circulation by chemokines, with the ability to kill 
pathogen.  
51 
Increased CXCR2 expression not only suggest that Fr. III leukocytes can be 
recruited in to circulation, but that the changes they undergo in the BM can also 
allow them to infiltrate tissues as well. To investigate this, we conducted 
adoptive transfer experiments where CFSE (green fluorescent dye) labeled Fr. 
III leukocytes were intravenously (IV) injected into healthy recipient mice, in 
which zymosan peritonitis was subsequently induced. Surprisingly, our study 
showed that leukocytes transferred from mice in the recovery phase 
demonstrated a 5-fold increase in infiltration when compared to 0d healthy mice 
with ~80% of leukocytes arriving in 2.5 hours (Fig. 3.3E). Despite this finding, 
immature myeloid leukocyte accumulation in the peritoneum was gradual when 
compared to functionally primed mature PMN.  
3.3.4 G-MDSC expansion and immunosuppression in colitis-to-
recovery mice:  
Initially, we hypothesized that the immature effector population were a result of 
emergency myelopoiesis, as chronic colitis has been shown to induce this 
process in the BM. Emergency myelopoiesis is a process where immature 
myeloid leukocytes are released from the BM before maturation to replenish the 
circulating PMN population 77,223,229. However, recent studies have suggested 
that under the same conditions a portion of these leukocytes expand in the BM 
and differentiate into myeloid derived suppressor cells (MDSC), another type of 
myeloid leukocyte. MDSC are comprised of a heterogenous mixture of Ly6Chigh 
monocytes and Ly6G+ low-density granulocytes, like what was observed in Fr. 
III. MDSC are derived from the same hematopoietic progenitors as PMN 
44,99,106,129,223,236. Therefore, MDSC can be activated by many of the same 
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inflammatory factors as PMN, especially IL-6 and GM-CSF and share many of 
the same proteins. Unfortunately, this makes it difficult to phenotypically 
distinguish between the two myeloid populations. Despite this, MDSC can be 
identified by the gain of two distinct attributes, 1) the ability to enter circulation 
before maturation and 2) potent inhibition of T lymphocyte responses 
83,97,105,108,117,126,225.  
 
The most efficient way to determine if the Fr. population are inflammatory PMN 
precursors or MDSC is to test for T cell inhibition capabilities. To do this, 
splenic T cells from healthy C57BL/6 mice were labeled with CFSE, a green 
fluorescent dye with an ester. Once in the cell, the ester on CFSE is cleaved so 
that the dye cannot exit the cell, therefore fluorescence will decrease only when 
cells proliferate. Following labeling with CFSE, T cell proliferation was induced 
by antibody ligation of T cell receptor (TCR) proteins CD3 and CD28. Fr. III 
myeloid leukocytes were then added to this system at a 1:6 ratio of leukocytes: 
splenocytes. After being cultured for 4d, the decrease of CFSE fluorescence in 
the T cells was analyzed by flow cytometry. In Fig. 3.4A, we show that Fr. III 
low-density myeloid leukocytes demonstrate potent inhibition of T cell 
proliferation at the post-acute stage (9d) with inhibition continuing through 
complete inflammation resolution (30d).  
 
Studies suggest that arginase-1 (ARG-1) expression plays an important role in 
MDSC suppression of T cells. Specifically, ARG-1 mediated depletion of L-
arginine from the microenvironment is thought to impede T cell development, 
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expansion, and effector functions 76,111-113,116. Therefore, upon finding that Fr. III 
leukocytes gain immunosuppressive capabilities, we decided to examine ARG-1 
expression. Indeed, we show that like our cancer models, ARG-1 expression was 
induced in these leukocytes only after coculture with CD3/CD28 activated 
splenocytes (Fig. 3.4B). Fr. III leukocytes collected from mice in the post-acute 
and recovery stages of treatment (12, 18, and 21d) displayed induction of ARG-1. 
As ARG-1 is primarily expressed by M2 macrophages and MDSC, these findings 
indicate that these leukocytes are MDSC 20,110.  
 
Since Fr. III contains a mixture of Ly6C high and Ly6G+ leukocytes, magnetic-
activated cell sorting (MACS) was used to further separate MDSC into the 
granulocytic and monocytic subpopulations. Testing these separated populations 
revealed monocytes in the BM display inhibition of T cells, even in healthy 
animals, suggesting that a percentage of leukocytes may be M-MDSC even at 
homeostasis. On the other hand, G-MDSC gained inhibitory functions during the 
post-acute stage that lasted throughout inflammation resolution (Fig. 3.4 D). 
Despite this, Fig. 3.4 C shows that the expanded population of Fr. III leukocytes 
were primarily comprised of Ly6G+CXCR2high G-MDSC (~41%), that displayed 
enhanced infiltration during our adoptive transfer experiments. Taken together, 
these data imply that G-MDSC are the primary subset playing a role in DSS- 
induced colitis.  
54 
3.3.5 G-MDSC accumulate in the spleens and colons of colitis-to-
recovery mice. 
MDSC are typically associated with tissue repair in healthy individuals and 
tumor progression in cancer where they promote an immune-tolerant host 
condition 102,103. However, the role of MDSC in chronic inflammation is still 
under investigation. Spleens of colitis-to-recovery mice were examined to 
investigate the role of MDSC in the periphery. Flow cytometric analyses of 
myeloid leukocytes in the spleen of recovery mice demonstrated a 5-fold increase 
in the percent of Ly6G+ granulocytes, recapitulating the expansion that was 
observed in the BM (Fig. 3.5A). Expansion of granulocytes during resolution was 
tightly correlated with an overall decrease in CD4 and CD8 T cells in the spleen 
(Fig. 3.5B). Since PMN infiltrate tissues primarily during chronic inflammation, 
it was hypothesized that expanded population were immunosuppressive MDSC.   
 
Since high numbers of granulocytes were found in the spleens of treatment mice, 
we postulated that G-MDSC may infiltrate colonic tissues during inflammation 
recovery. To test this, histopathological staining of colon tissues from mice at 
various stages of treatment was conducted. Indeed, we show that high numbers 
of granulocytes were found in murine colons at the post-acute phase. During 
inflammation resolution, ARG-1+ Ly6G+ cells were identified in colons 
displaying tissue repair morphology (Fig. 3.5 C).  Furthermore, Ly6G+ leukocyte 
accumulation in the colon tightly correlated with expression of tissue repair 
markers Ki67 (proliferation) and a-smooth muscle actin (a-SMA). Collectively, 
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these data suggest that ARG-1+ Ly6G+ cells present in the colon during 
inflammation resolution are G-MDSC and likely play a role in tissue repair.  
3.4 Discussion  
PMN were found to display enhanced infiltration and response in multiple 
chronic inflammatory models, but particularly during DSS-induced colitis 
26,66,178,188. Our previous study revealed that enhanced PMN infiltration and 
response were a result of changes to the myeloid compartment of the BM during 
the post-acute stage of DSS treatment 1. Despite these findings, there are few 
studies investigating the magnitude of PMN alternations in the BM before they 
are recruited into circulation. In our studies, PMN numbers were significantly 
decreased in the BM of mice with post-acute colitis. Simultaneous extensive 
expansion of immature CD11b+Gr1+ myeloid leukocytes was also observed in the 
BM of DSS treated mice. These leukocytes were originally thought to be 
comprised primarily of PMN precursors. Later, it was found that they instead 
resembled MDSCs, which are a heterogeneous population of immature 
immunosuppressive monocytes (M-MDSCs) and granulocytes (G-MDSCs) 
76,96,105,106,236. Clearly, the mechanisms by which chronic inflammatory 
conditions and particularly colitis, alter myelopoiesis to induce both pro-
inflammatory and immunosuppressive myeloid leukocytes are complex. 
Understanding the role of the expanded population of MDSC in colitis will not 
only help to elucidate these mechanisms, but also evaluate their therapeutic 
potential in ulcerative colitis.  
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In DSS-induced colitis-to-recovery mice, the immature granulocyte population- 
which were later confirmed to be G-MDSCs- significantly expanded in the BM at 
the post-acute stage. These cells comprised majority of the expanded CD11b+Gr-
1+ myeloid leukocyte population. On the other hand, numbers of immature 
Ly6Chigh monocytes/M-MDSCs displayed no significant changes throughout 
colitis-to-recovery treatment. Although expansion of G-MDSC was associated 
with significant decreases in the mature granulocyte (PMN) population, it was 
predicted that this was correlative and not causal, as PMN are mobilized in high 
numbers from the BM during chronic inflammation. In fact, PMN and more 
recently G-MDSC have been identified in the circulation and tissues of patients 
with ulcerative colitis 4,25,57,93,95,96,171,237. These studies suggest chronic 
inflammation induces emergency myelopoiesis in the BM. This conclusion agrees 
with various human chronic inflammatory disease studies, in which emergency 
myelopoiesis are reported to occur 77,223,229. Additionally, this conclusion is in 
agreement with the theory that chronic inflammation induced emergency 
myelopoiesis produces not only PMN precursors, but also immature myeloid 
leukocytes that can expand and differentiate to MDSC after stimulation by serum 
cytokines 77. The role of MDSC in chronic inflammatory diseases is controversial 
as they have been shown to display both pro-inflammatory and 
immunosuppressive characteristics in different models of chronic intestinal 
inflammation 76,93,102,114,136,142,238.    
 
The data collected revealed that G-MDSCs induced by chronic inflammation are 
distinct from healthy immature granulocytes and mature PMN. MDSC 
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demonstrated T cell inhibitory capacity, expression of ARG-1, and increased 
expression of CXCR2 when compared to healthy immature granulocytes. 
Elevated CXCR2 expression allows G-MDSC to gain egress from the BM and 
enter into circulation, which is not the case in healthy conditions where low 
expression of CXCR2 restrains immature granulocytes to the BM 12,22,93,235. 
Despite this finding, G-MDSC still shared some characteristics with immature 
granulocytes such as, cell density, complexity indicated by SSC value, and non-
segmented nuclei. Thus, G-MDSC resemble true effector cells with the ability to 
be released into circulation and perform immunosuppressive functions 
elsewhere in the body. PMN and G-MDSC adoptively transferred from 
chronically inflamed mice to healthy donor mice both demonstrated enhanced 
infiltration during zymosan-induced peritonitis. However, in comparison with 
PMN, which accumulated in the peritoneum during the height of post-acute 
inflammation, MDSC were found to accumulate, albeit in smaller amounts, late 
in the post-acute phase closer to inflammation recovery. These results not only 
indicate that PMN become functionally primed in the BM of chronically inflamed 
mice, but that G-MDSC may infiltrate the colon during tissue repair. Indeed, 
PMN infiltration of the colon is required for clearance of commensal bacteria 
that can act as a driving force of colitis, but the deleterious effects caused by 
their enhanced responses greatly promote colitis pathology as well 4,6,25,47,51,68. 
Therefore, it is plausible that the chronically inflamed microenvironment 
releases signals to alter myelopoiesis and produce immunosuppressive 
granulocytes to balance the effects of PMN and other pro-inflammatory cell 
types including CD4 and CD8 T lymphocytes, so that all the processes required 
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to initiate inflammation resolution can occur. Reports by Su et al., and Guan et 
al., demonstrated that adoptive transfer of MDSC to mice with intestinal 
inflammation resulted in decreased IFN-γ, TNF-α, IL-17, IL-6 expression, and 
myeloperoxidase activity in the colonic mucosa, all of which have been found to 
contribute to leukocyte recruitment, activation, and effector functions 138,140. If 
this is the case, induction of G-MDSC could be a therapeutic treatment option 
for patients with chronic inflammation. 
 
To determine the therapeutic potential of MDSC, their role in chronic 
inflammation must be elucidated. Studies show that in experiments where 
MDSCs were adoptively transferred to in vivo models of rheumatoid arthritis 
(RA) and experimental autoimmune encephalomyelitis (EAE) they alleviated 
symptoms associated with each disease. A protective role of MDSC in allogeneic 
transplantation has also been documented 136-138,142,238. In our study, expansion 
of G-MDSC in the spleens of DSS-induced colitis-to-recovery mice corroborated 
these findings, as it was accompanied by an overall decrease in splenic CD3+ T 
cells. This suggest that MDSC in the spleens of colitis mice inhibit the 
proliferation of T splenocytes, disrupting their recruitment into the inflamed 
colonic mucosa. Continuous infiltration of leukocytes, especially PMN and T 
lymphocytes, have been shown to promote colitis pathology 3,10,14,15,36,43,74,219. 
Furthermore, ARG-1 expressing Ly6G+ granulocytes were observed in the colons 
of mice during inflammation recovery. This was tightly correlated with increased 
expression of Ki-67 and a-SMA, which are cell proliferation and repair proteins 
that are generally elevated during tissue remodeling under chronic inflammatory 
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conditions 239,240. In accordance with this, a study conducted by Zhang et al., 
revealed that MDSCs transferred to colitis mice reduced inflammation and more 
importantly facilitated colonic mucosal healing. MDSC have also been reported 
to contribute to tissue repair in healthy individuals 102,139,234,241. Despite this 
evidence the role of MDSC remains controversial, as some studies have shown 
that G-MDSC- like cells in the colon of mice with colitis gained APC functions, 
induced T cell activation and pro-inflammatory cytokine production 54,96. Based 
on these data, it is reasonable to conclude that suppression of leukocyte 
infiltration and responses by G-MDSC facilitates inflammation resolution, 
thereby promoting colon tissue repair.  
 
Although these results provide crucial insight about the changes that occur to 
the myeloid compartment under chronic inflammatory conditions, the factor(s) 
that induce these alterations are still under investigation. IL-17 is highly 
expressed in the serum and colonic mucosa of ulcerative colitis patients 
1,63,149,154,155,165. Specifically, elevated expression of IL-17 has been shown to 
perpetuate chronic colitis through regulation of PMN differentiation, activation, 
and recruitment from the BM. Despite this observation, attempts to neutralize 
IL-17 with antibodies in ulcerative colitis patients were unsuccessful but resulted 
in exacerbation of the disease 155,159,161-164,166,169.  
 
Exacerbation of colitis symptoms in IL-17 neutralized patients indicated that IL-
17 plays a more complex role in colitis than originally thought. Research 
investigating this phenomenon suggest that the exacerbated colitis pathology 
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induced by inhibition of IL-7 expression could be attributed to increased 
invasion of commensal bacteria as a result of impaired PMN infiltration and 
response. Additionally, IL-17, in conjunction with IL-22, was found to help 
maintain tight epithelial junctions and promote epithelial cell regeneration in 
the intestine. Therefore, IL-17s inhibition in colitis models could also contribute 
to disease exacerbation in a similar mechanism 143,144,149. In our study, IL-17 was 
still elevated in the serum of DSS-induced colitis-to-recovery mice, albeit at 
lower levels, during inflammation resolution when expansion of G-MDSC was 
observed. Considering these findings, it is also plausible that inhibition of IL-17 
may have blocked MDSC expansion, thereby removing the immunosuppressive 
leukocytes that may help to balance inflammatory responses in the colon. 
However, IL-17s role in the development of MDSC has yet to be studied in 
chronic colitis. IL-17 is known to induce factors needed for PMN regulation, 
especially IL-6 and GM-CSF, which have also been found to induce MDSC under 
disease conditions. It has also been shown to induce production of other myeloid 
leukocyte stimulatory factors associated with MDSC expansion such as G-CSF, 
IL-4, and Il-10 95,116,138,142,225. Most studies suggest at least two or more cytokines 
from the aforementioned factors are required for induction of MDSC during 
chronic inflammation. Since, IL-17 has been found to induce secretion of these 
factors by various cells subsets in the intestine, such as epithelial cells, it can be 
hypothesized that it may act as an upstream master regulator of MDSC 
development. Recent studies utilizing in vivo models of colorectal cancer and 
Lewis lung carcinoma provide evidence that IL-17 not only promotes expansion 
of MDSC, but also inhibits their apoptosis in the tumor microenvironment 226,227.   
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Figure 3.1. An active inflammation-recovery mouse model. 
A) Scheme of DSS-induced colitis–recovery model in C57BL/6 mice. Mice ~20g were treated with 2% DSS 
in drinking water for 9 d, followed by 21 d of pure water to allow for recovery. Indicators of disease 
progression and recovery were monitored. B) Percent body weight loss for colitis-recovery and control 
mice. C) Disease activity index score (DAI). Body weight loss, stool consistency, and bloody stool were 
scored on a scale of 1-3 and averaged. n = 5 D) Assessment of colon tissue damage by measuring colon 
length. E) Pro-inflammatory cytokine (IL-17, IL-6, IFN-γ and GM-CSF) expression in the serum of DSS-
colitis mice were assayed using ELISA. F) Measurement of fecal lipocalin-2 (LCN-2) by ELISA for colitis-
to-recovery mice. Data are represented as median ± SEM. Significant differences were determined by 
student T test * p ≤ 0.05, ** p ≤ 0.001, *** p ≤ 0.0001 versus respective controls.   
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Figure 3.2. Percoll separation of bone marrow leukocytes. 
A) BM harvested from healthy and DSS-recovery mice were applied to discontinuous Percoll density 
gradients and centrifuged. Four cell-enriched fractions (Fr. I, II, III, and IV) were formed at sequentially 
increased density interfaces (70, 60, 50, 40, and 5%). B) FACS analysis of CD11b+, Ly6Chigh and Ly6G+ 
BM leukocytes. C) Analyses Ly6G+ granulocytes in Fr. III & IV for FSC and SSC values. D) Progressive 
expansion of Fr. III Ly6G+ granulocytes in mice under colitis-to-recovery treatment. Graph is expressed 
as median ± SEM. Significant differences were determined by student T test * p < 0.05, ** p < 0.01, *** p 
< 0.001 versus respective controls. These data represents > five independent experiments with three mice 
per experiment.  
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Table 3-1. Dynamic changes in the myeloid compartment during DSS-induced colitis-
recovery.  
Leukocytes from colitis-to-recovery mice were harvested from femur and tibia bones, this 
was followed by Percoll gradient separation. Total BM cells prior to separation and cells 
distributed in Fr. I to IV were counted. Ly6Chigh and Ly6G+ cells in Fr. III were determined 
by FACS. The significant differences between the tested groups were calculated by one-way 
ANOVA followed by Dunnett’s Multiple Comparison test. a) p 0.001 
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Figure 3.3. Functional alteration of the myeloid compartment. 
A) PMA-induced ROS production in mature PMN determined by DCFDA 
staining. B) In vivo granulocyte trafficking to peritoneum. Isolated Fr. IV 
mature PMN from colitis-to-recovery mice were labeled with fluorescence dye 
CMTMR (red). Red leukocytes from Fr. IV were then transferred into healthy 
recipients. Following this, to induce PMN infiltration mice were immediately 
injected with zymosan. At 2.5 hr post-injection the contents of the peritoneal 
cavity were collected and analyzed for colored granulocytes within 
CD11b+Ly6G+ cells. C) FACS analysis of CXCR2 surface expression on Fr. III 
Ly6Chigh and Ly6G+ BM leukocytes. D) PMA-induced ROS production in Fr. III 
Ly6Chigh and Ly6G+ leukocytes, determined by DCFDA staining. E) Isolated Fr. 
III Ly6Chigh and Ly6G+ granulocytes from colitis-to-recovery mice were labeled 
with fluorescence dye, CFSE (green). Green granulocytes of Fr. III were then 
transferred into healthy recipients. Following this, zymosan peritonitis was 
induced for 2.5 hr. All graph data is expressed as median ± SEM, Significant 
differences for (A,B,C) were determined by student T test, and one- way ANOVA 
(D,E) * p < 0.05, ** p < 0.01, *** p < 0.001 versus respective controls 
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Figure 3.4. G-MDSC expansion and immunosuppression. 
A) Assay for Fr. III leukocyte mediated inhibition of T-cell proliferation. Splenic 
T cells labeled with CFSE were induced to proliferate by antibody ligations of 
CD3 and CD28 (CD3/CD28) in the absence (control) or the presence of Fr. III 
myeloid leukocytes at a ratio of 1:8 leukocytes: splenocytes. After 4 days (4d), 
the proliferation of T cells, both CD4 and CD8, was determined by flow 
cytometric analyses of CSFE dilution (left shift). NC, no proliferation induction. 
B) Western blot detecting arginase-1 in band III BM leukocytes before (-) and 
after (+) co-culturing these cells with T cells proliferation media. C) Analysis of 
Fr. III Ly6Chigh and Ly6G+ cell numbers in treatment mice D) Inhibitory effect 
of M-MDSC and G-MDSC on T-cell proliferation. Fr. III MDSC were further 
separated into M-MDSC and G-MDSC by Ly6C and Ly6G selection, respectively, 
prior to testing in T-cell proliferation assays. The MDSC: splenocytes = 1:6. 
Significant differences (C) analyzed by student T test * p < 0.05, ** p < 0.01, *** 
p < 0.001 versus respective controls.  
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Figure 3.5. G-MDSC accumulate in the spleens and colons of colitis-to-recovery mice.  
A) Expansion of Ly6Chigh and Ly6G+ myeloid leukocytes in the spleens of recovery 
mice determined by FACS. B) FACS analysis of CD4 and CD8 T splenocytes in mice 
throughout colitis-to-recovery treatment. C) H&E and Immunofluorescent staining for 
Ly6G, Ki67, and a-SMA in colons from mice under DSS-induced colitis-to-recovery 
treatment. All graph data is expressed as median ± SEM, Significant differences were 
determined by one-way ANOVA *p < 0.05, ** p < 0.01, *** p < 0.001 
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4 CONCLUSIONS 
The concepts reviewed in this dissertation coupled with our findings have led to 
several conclusions. Specifically, my data suggest that when a healthy mouse 
becomes chronically inflamed, systemically elevated IL -17 induces a 
reprograming event in the myeloid compartment of the bone marrow (BM). 
Based on the research available, I believe that IL-17 may induce secretion of 
myeloid leukocyte stimulatory factors to indirectly act on PMN and MDSC. The 
literature shows that IL-17 is induces release of IL-6 and GM-CSF by fibroblast 
and stromal cells in the BM 81,145,149,154,159,242. Elevated expression IL-6 and GM-
CSF in the BM has been found to activate transcription factors, including NF-κB, 
P38/MAPK, C/EBPβ and SOCS3, that initiate emergency myelopoiesis. A major 
outcome of emergency myelopoiesis is the production of altered subsets of 
myeloid leukocytes 77,221-223,229. Although studies have investigated how myeloid 
leukocytes produced by emergency myelopoiesis are altered in the tissues, 
research on these subsets in the BM is not as common.  
 
Analyzing the BM of DSS-induced colitis-to-recovery mice recapitulated findings 
that the myeloid compartment is altered under chronic inflammatory conditions 
1,203. Indeed, my work shows that both immature and mature myeloid leukocyte 
population sizes changes dynamically throughout treatment. The mature PMN 
subset steadily decreased during the post-acute phase of treatment. Despite 
decreases in numbers, PMN displayed enhanced infiltration and responses. In 
fact, PMN infiltration and ROS production was at its highest when their 
numbers in the BM were at their lowest (9d). This suggest that PMN are 
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functionally primed early in chronic inflammation in preparation for mass 
recruitment from the BM.  
 
Surprisingly, the immature myeloid leukocyte population rapidly expanded 
during chronic colitis. Unlike PMN, peak immature myeloid leukocyte expansion 
occurred at 12d in the BM. This was coupled with increased expression of CXCR, 
ROS production, and infiltration. Immature leukocytes remained altered until 
the end of resolution ~30d. Increased migratory capabilities and pathogen 
removal abilities beginning in late stage post-acute inflammation indicate that 
these leukocytes migrate into the inflamed mucosa toward the end of 
inflammation. 
 
In acute inflammation, PMN are thought to be primed in circulation and during 
transmigration into the inflamed area so that they can infiltrate the tissue and 
rapidly preform their functions 4-6. Our study suggests that when the condition 
becomes chronic, similar to what was observed in our post-acute colitis mice, 
functional priming of PMN occurs in the BM and this contributes to the 
enhanced infiltration and response we see under ulcerative colitis conditions. 
Therefore, these enhanced inflammatory leukocytes are likely a consequence of 
continuous pro-inflammatory signals being sent in the serum from the 
unresolved intestinal microenvironment. Functionally altered PMN may develop 
as a mechanism to deal with the unresolved insult, but it is more likely that 
under these conditions they significantly contribute tissue damage in the colon 
as well.  
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Significant expansion of immature granulocytes, identified to be G-MDSC by 
expression of ARG-1 and potent suppression of T cell proliferation, were also 
observed during post-acute inflammation. G-MDSCs displayed increased 
expression of CXCR2, which indicated gain of migratory capabilities that are not 
demonstrated by healthy immature granulocytes. Indeed, immunofluorescent 
staining of colitis-to-recovery colons revealed that G-MDSC accumulate in the 
colon of DSS treated mice during post-acute inflammation and resolution. 
Additionally, the presence of granulocytes in spleens of these mice tightly 
correlated with decreases in splenic CD3+ CD4 and CD8 T cells.  
 
While the role of G-MDSC in chronic colitis is still under investigation, based on 
their presence in the colon and potent inhibition of T cells in ex vivo assays, we 
hypothesize that MDSC suppress the responses of leukocytes, especially T cells 
in the inflamed colon. MDSC have been associated with tissue repair in several 
studies, including ours where we show high expression of tissue repair markers 
Ki-67 and a-SMA when G-MDSC are present in the colon. MDSC have also been 
shown to suppress multiple other pro-inflammatory leukocytes and induce 
immunosuppressive cell types such as T regulatory cells (Treg) and M2 
macrophages 83,87,95,130,131,225. Collectively, these studies suggest that G-MDSCs 
impair the responses of leukocytes, including T cells, PMN, and M1 macrophages 
to counteract the effects of their exacerbated response in the inflamed colonic 
mucosa, thereby promoting inflammation resolution. 
  
77 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Altered myelopoiesis in the bone marrow of colitis mice.  
Schematic depiction of the reprogramming that occurs in the myeloid 
compartment of the BM during chronic inflammation.   
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